# Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

> **NCT01724346** · PHASE3 · COMPLETED · sponsor: **Pharmacyclics LLC.** · enrollment: 269 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma

## Interventions

- **DRUG:** Ibrutinib
- **DRUG:** Next-line ibrutinib

## Key facts

- **NCT ID:** NCT01724346
- **Lead sponsor:** Pharmacyclics LLC.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12-03
- **Primary completion:** 2023-08-18
- **Final completion:** 2023-08-18
- **Target enrollment:** 269 (ACTUAL)
- **Last updated:** 2024-09-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01724346

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01724346, "Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT01724346. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*